HematologyPfizer
Pfizer Reports Positive Phase 3 BASIS Trial Results for Marstacimab in Hemophilia
BMI
Biotechnology Media Insights
Editorial Team · April 18, 2025
Pfizer announces positive Phase 3 BASIS trial results showing marstacimab significantly reduces bleeding rates in patients with hemophilia A or B without inhibitors.
Pfizer today announced positive results from the Phase 3 BASIS trial evaluating marstacimab, an anti-TFPI antibody, in patients with severe hemophilia A or B without inhibitors. The trial met its primary endpoint, demonstrating a significant reduction in treated bleeding rate compared to prior prophylaxis.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.